Souhaitez-vous accéder aux communiqués récents ?

Kansas City, Mo., Feb. 12, 2026 (GLOBE NEWSWIRE) -- CRB announced today that John R. Lupa, Jr. has joined the firm as Vice President, National Construction. An engineering, construction and...

New york, USA, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Idiopathic Pulmonary Fibrosis Clinical Trials & Pipeline Overview: Insights into 80+ Leading Companies and 100+ Novel Treatments | DelveInsight ...

Chicago, Feb. 09, 2026 (GLOBE NEWSWIRE) -- The global Idiopathic pulmonary fibrosis market generated US$ 2,970.69 million in 2025 and is estimated to reach US$ 6,736.49 million by 2035, growing at a...

Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the current standard of care, OCREVUS, in...

SEATTLE, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the...

Dublin, Feb. 03, 2026 (GLOBE NEWSWIRE) -- The "Antibody Drug Conjugates Market Forecasts (2026-2030) by Cancer, Payload, Target, Product, User and Country/Region with Executive and Consultant...

BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a...

Breakthru Medicine emerges from stealth with $60M Series A in cancer drug development

Dr. Mobasher held several executive roles in industry, most recently CMO at BeiGeneIFLI contributed up to $9 million to Enterome’s private funding round in 2025Enterome has announced a series of...

Group sales grew by 7%1 at constant exchange rates (CER; 2% in CHF), driven by strong demand for medicines and diagnostic solutions.Sales in the fourth quarter increased by 8%, reflecting the positive...